Novartis AG ADR (NVS)vsPrenetics Global Ltd (PRE)
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
PRE
Prenetics Global Ltd
$20.79
-0.19%
HEALTHCARE · Cap: $319.78M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 61138% more annual revenue ($56.58B vs $92.39M). NVS leads profitability with a 23.9% profit margin vs -40.8%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
PRE
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for PRE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 248.6% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -22.1% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PRE
The strongest argument for PRE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 248.6% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : PRE
The primary concerns for PRE are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while PRE is a hypergrowth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
PRE is growing revenue faster at 248.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 32/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Prenetics Global Ltd
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Prenetics Global Ltd (PRE) is a leading health technology innovator specializing in advanced genetic and diagnostic testing solutions that empower both consumers and healthcare providers with essential health insights. The company has experienced robust international expansion, supported by strategic partnerships and a relentless focus on research and development. Positioned at the forefront of personalized medicine, Prenetics is well-equipped to meet the growing demand for accessible and actionable health information, making it a notable investment opportunity within the evolving healthcare sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?